Spyre Therapeutics Inc. (SYRE NASDAQ) stock market data APIs
$103.2597
-1.68(-1.6%)
as of November 13, 2026
Try our APIs with
free plan!
Spyre Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Prev. Close
103.2597
Open
101.5766
High
104.1414
Low
100.1928
52 wk Range
23.01-110.64
Market Cap
9 877 M
Shares Outstanding
94 969 K
EPS
-0.94
Beta
3.227
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Spyre Therapeutics Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Spyre Therapeutics Inc. data using free add-ons & libraries
Get Spyre Therapeutics Inc. Fundamental Data
Spyre Therapeutics Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -207 822 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-03
- EPS/Forecast: -0.79
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Spyre Therapeutics Inc. News
New
Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview
Spyre Therapeutics has seen its share price move sharply in recent years, so the question now is whether a US$90.33 stock is adequately supported by what sits on its balance sheet. With the market foc...
Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says
Spyre Therapeutics' (SYRE) combination therapy approach for inflammatory bowel disease gained furthe PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation ther...
Spyre Therapeutics prices $350M public offering at $85 per share
Spyre Therapeutics (SYRE [https://seekingalpha.com/symbol/SYRE]) announced the pricing of its underwritten public offering [https://seekingalpha.com/pr/20675238-spyre-therapeutics-announces-pricing-of...
Get Spyre Therapeutics Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.